Table 2:

SUMMARY OF RECENT STUDIES OF HIV D+/R− TRANSPLANTATION

Author	Study Name	Center	Transplant recipients (n)	HCV Donor NAT+ (n, %)	Genotype (n)	Prophylactic or preemptive DAA approach	DAA Therapy (n)	SVR12 or transmission prevention (n, %)
Goldberg et al. (2017) [56]	THINKER	University of Pennsylvania	Kidney (20)	13/13 (100%)	1 (13)	Preemptive	Elbasvir/grazoprevir x 12 weeks (20)	20/20 (100%)
Durand et al. (2018) [57]	EXPANDER	Johns Hopkins University	Kidney (10)	10/10 (100%)	1a (3) 1a/3 (1) 2 (1) 3 (1) Indeterminate (4)	Prophylactic	Elbasvir/grazoprevir x 12 weeks (7) Elbasvir/grazoprevir/ sofobuvir x 12 weeks (3)	10/10 (100%)
Durand et al. (2020) [58,*]	REHANNA	Johns Hopkins University	Kidney (10)	10/10 (100%)	1a (6) 1b (1) 3 (2) Indeterminate (1)	Prophylactic	Glecaprevir/pibrentasvir x 4 weeks (10)	10/10 (100%)
Gupta et al. (2019) [59,**]	DaPPER	Virginia Commonwealth University	Kidney (50)	27/27 (100%)	1a (19) 2 (2) 3 (6)	Prophylactic	Sofosbuvir/velpatasvir x 2 days (10) Sofosbuvir/velpatasvir x 4 days (40)	7/10 (70%) 37/40 (93%)
Feld et al. (2020) [61,**]	N/A	University of Toronto	Lung (13) Kidney (10) Heart (6) Kidney-pancreas (1)	18/18 (100%)	1 (9) 2 (2) 3 (5) Unknown (2)	Prophylactic	Ezetimibe and glecaprevir/pibrentasvir x 8 days (30)	30/30 (100%)
Terrault et al. (2020) [53**]	PRO-ACT	Multicenter	Liver (13) Kidney (11)	13/13 (100%)	Not reported	Preemptive	Sofosbuvir/velpatasvir x 12 weeks	13/13 (100%) 10/10 (100%)
Reese et al. (2018) [63]	USHER	University of Pennsylvania	Heart (10)	10/10 (100%)	1a (10)	Preemptive	Elbasvir/grazoprevir x 12 weeks (9)	9/10 (90%)
Wooley et al. (2018) [64]	DONATE-HCV	Brigham and Women’s Hospital	Lung (36) Heart (8)	41/41 (100%)	1a (24) 1b (1) 2 (7) 3 (7) Indeterminate (2)	Preemptive	Sofosbuvir/velpatasvir x 4 weeks (44)	35/35 (100%)